Nancy Lurker of EyePoint Pharmaceuticals Addresses Innovations in Eye Care, How to Grow in the C-Suite and What it Takes to Run a Biopharma Company

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.

The annual dilated retinal exam, a unique tool which uses drops to dilate the pupil, is not just about eye health. It offers a comprehensive view of a member's overall well-being, potentially identifying serious health issues at an early stage.

Briana Contreras, an editor of Managed Healthcare Executive, spoke with Brian Adams, President and CEO of Tabula Rasa HealthCare, in this month's episode of Tuning In to the C-Suite podcast.

The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.

Lack of standardization has obscured complication rates in clinical trials, say a team of researchers. In results reported in the journal Ophthalmology earlier month, they list 67 ocular complications that experts agreed upon using a Delphi process,